158 related articles for article (PubMed ID: 18402243)
1. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Jan; 149 Suppl 4():172-81. PubMed ID: 18402243
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Fogari R; Mugellini A; Derosa G;
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
[TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Ketelhut R; Bramlage P
Clin Drug Investig; 2010; 30(5):301-11. PubMed ID: 20384386
[TBL] [Abstract][Full Text] [Related]
4. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
6. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Mengden T; Uen S; Bramlage P
Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Edes I;
Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
[TBL] [Abstract][Full Text] [Related]
8. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
Bönner G; Landers B; Bramlage P
Vasc Health Risk Manag; 2011; 7():85-95. PubMed ID: 21415922
[TBL] [Abstract][Full Text] [Related]
9. [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Uen S; Un I; Fimmers R; Vetter H; Mengden T
Dtsch Med Wochenschr; 2007 Jan; 132(3):81-6. PubMed ID: 17219340
[TBL] [Abstract][Full Text] [Related]
10. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
[No Abstract] [Full Text] [Related]
11. Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension.
Setiawati A; Pohan T
Acta Med Indones; 2013 Jul; 45(3):193-201. PubMed ID: 24045389
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
13. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Mugellini A; Nieswandt V
Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
15. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.
Kawamori R; Fujita T; Matsuoka H; Umemura S; Saito Y
Diabetes Res Clin Pract; 2009 Feb; 83(2):241-8. PubMed ID: 19097664
[TBL] [Abstract][Full Text] [Related]
16. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
[TBL] [Abstract][Full Text] [Related]
17. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Oparil S
Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Neldam S; Forsén B;
Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
[TBL] [Abstract][Full Text] [Related]
19. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
20. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
Bramlage P; Buhck H; Zemmrich C
Clin Drug Investig; 2014 Apr; 34(4):241-9. PubMed ID: 24482018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
